文献速递冠心病

超薄西罗莫司洗脱支架与依维莫司洗脱支架在糖尿病多支冠状动脉病变患者中的对比:TUXEDO-2 试验

Ultra-Thin Sirolimus-Eluting Versus Everolimus-Eluting Stents in Diabetic Multivessel Coronary Artery Disease Patients: The TUXEDO-2 Trial.
PubMed 文献 · J Am Coll Cardiol · 2026-07-01

TUXEDO-2 为研究者发起的前瞻性、开放标签、多中心、2×2 析因、1:1 随机对照试验,纳入 1800 例接受经皮冠状动脉介入治疗的糖尿病多支病变患者,比较超薄可降解聚合物西罗莫司洗脱支架(SES)与持久聚合物依维莫司洗脱支架(EES)。1 年随访时,主要终点靶病变失败率在 SES 组为 7.92%、EES 组为 8.75%,风险差异 -0.83 个百分点(单侧 97.5% 置信上限 3.42%),满足预设非劣效界值 4.5%(PNI=0.005)。

要点

  • 糖尿病多支病变患者中,超薄可降解聚合物 SES 在 1 年靶病变失败方面不劣于持久聚合物 EES。
  • 两组心源性死亡、靶血管心肌梗死及缺血驱动的靶病变血运重建率无显著差异。
  • 非致命性心肌梗死与支架内血栓发生率在两组间相似。

核心结论

  • 在糖尿病多支病变接受经皮冠状动脉介入治疗的患者中,超薄可降解聚合物西罗莫司洗脱支架在 1 年随访时不劣于持久聚合物依维莫司洗脱支架。

研究设计与样本

  • TUXEDO-2 为研究者发起的前瞻性、开放标签、多中心、2×2 析因、1:1 随机对照试验,共随机 1800 例患者,平均年龄 60.3 岁,女性占 28%。
  • 患者随机接受 Supraflex Cruz 西罗莫司洗脱支架或 Xience 依维莫司洗脱支架,并同时随机接受替格瑞洛或普拉格雷治疗。
  • 主要终点为 1 年随访时靶病变失败,即心源性死亡、靶血管心肌梗死或缺血驱动的靶病变血运重建的复合终点;试验设计检验可降解聚合物 SES 相对于持久聚合物 EES 的非劣效性,非劣效界值为 4.5%(单侧 97.5% 置信上限)。

主要发现

  • 1 年时主要终点靶病变失败共发生 148 例,其中可降解聚合物 SES 组 70 例(7.92%),持久聚合物 EES 组 78 例(8.75%)。
  • 风险差异为 -0.83 个百分点(单侧 97.5% 置信上限 3.42%),满足预设非劣效界值(PNI=0.005)。
  • 两组心源性死亡(3.6% 对 3.4%)、靶血管心肌梗死(6.61% 对 7.54%)及缺血驱动的靶病变血运重建(0.8% 对 1.0%)均无显著差异。
  • 非致命性心肌梗死(4.7% 对 6.4%)与支架内血栓(1.0% 对 0.7%)在两组间相似。

关键数值与推荐

  • 非劣效界值设为 4.5%(单侧 97.5% 置信上限),实际风险差异 -0.83 个百分点(单侧 97.5% 置信上限 3.42%),PNI=0.005。
  • 1 年靶病变失败率:可降解聚合物 SES 组 7.92%,持久聚合物 EES 组 8.75%。

临床怎么用

  • 对于接受经皮冠状动脉介入治疗的糖尿病多支病变患者,超薄可降解聚合物西罗莫司洗脱支架可作为持久聚合物依维莫司洗脱支架的替代选择,1 年疗效不劣于后者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with diabetes frequently have multivessel disease and are at increased risk of adverse outcomes. The outcomes with a new-generation ultra-thin strut sirolimus-eluting stent (SES) vs everolimus-eluting stent (EES) is unclear as stent-to-stent comparison trials have routinely excluded these patients or included a small proportion of such patients. OBJECTIVES: The purpose of this study was to compare the clinical outcomes of ultra-thin biodegradable polymer (BP) SES vs durable polymer (DP) EES when combined with contemporary optimal medical therapy in patients with diabetes and multivessel disease. METHODS: The TUXEDO-2 is an investigator-initiated prospective, open-label, multicenter, 2 × 2 factorial, randomized (1:1) controlled trial. Patients undergoing percutaneous coronary intervention were randomized to receive either a Supraflex Cruz SES or Xience EES. The participants were also randomized to Ticagrelor or Prasugrel. The primary endpoint was target lesion failure, a composite of cardiac death, target vessel myocardial infarction or ischemia-driven target lesion revascularization at 1-year follow up. The trial was designed to test noninferiority of BP-SES vs DP-EES, with a noninferiority margin of 4.5% (1-sided upper 97.5% confidence bound). RESULTS: Among the 1,800 patients randomized, mean age was 60.3 years with 28% of participants being women. At 1 year, the primary endpoint of target lesion failure occurred in 148 patients, including 70 patients (7.92%) in the BP-SES group and 78 patients (8.75%) in the DP-EES group. The risk difference of -0.83 percentage points (1-sided upper 97.5% confidence bound 3.42%) met the prespecified noninferiority margin (PNI = 0.005). There were no significant differences in cardiac death (3.6% vs 3.4%), target vessel myocardial infarction (6.61% vs 7.54%), and ischemia-driven target lesion revascularization (0.8% vs 1.0%) between the 2 groups. Nonfatal myocardial infarction (4.7% vs 6.4%) and stent thrombosis was similar (1.0 % vs 0.7%) between the 2 groups. CONCLUSIONS: In patients with diabetes and multivessel disease undergoing percutaneous coronary intervention, ultra-thin biodegradable polymer SES was noninferior to durable polymer EES at 1 year follow-up. (Trial Registration Number CTRI/2019/11/022088).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Kaul U, Sinha SK, Singh R, et al. Ultra-Thin Sirolimus-Eluting Versus Everolimus-Eluting Stents in Diabetic Multivessel Coronary Artery Disease Patients: The TUXEDO-2 Trial. J Am Coll Cardiol. 2026. PMID: 42383943. doi:10.1016/j.jacc.2026.05.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。